Yunjuan Zhao, Lin Yang, Zhiguang Zhou. (2014) Dipeptidyl peptidase-4 inhibitors: Multitarget drugs, not only antidiabetes drugs (D ipeptidyl peptidase -4抑制剂:多靶点药物,不仅仅是降糖药). Journal of Diabetes 6 :10.1111/jdb.2014.6.issue-1, 21-29 /...
二肽基肽酶-4(Dipeptidyl peptidase-4,DPP-4)抑制剂是一种新型降糖药物,主要通过抑制内源性肠促胰岛素-胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽的降解而起到降血糖的作用。许多研究已证实DPP-4抑制剂对2型糖尿病患者的胰岛β细胞具有保护作用。DPP-4是一种在体内广泛表达的酶,由此推测DPP-4抑制剂是一种多...
Dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a novel class of anti-diabetic agents confirmed to improve glycemic control and preserve β-cell function in type 2 diabetes. Three major large-scale studies, EXAMINE, SAVOR-TIMI 53, and TECOS, have confirmed the cardiovascular safety profile o...
The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of endogenously released incretin hormones, represent a new therapeutic approach to the management of type 2 diabetes mellitus. The ‘first-in-...
Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv Exp Med Biol 2003; 524: 263–279. 9 Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003; 12: 87–100. 10...
R.C.L.Page, inSide Effects of Drugs Annual, 2008 Dipeptidyl peptidase IV inhibitors Dipeptidyl peptidase IV(DPP IV) is an enzyme that is involved in the rapid metabolism ofincretins, such as glucagon-like peptide. Inhibitors of DPP IV therefore extend the action of incretins. The incretins ...
(doi:10.1136/bmj.e1369), Karagiannis and colleagues present a systematic review and meta-analysis of the risks and benefits associated with one of the relatively new classes of oral hypoglycaemic drugs, the dipeptidyl peptidase-4 (DPP-4) inhibitors.2DPP-4 inhibitors reduce the breakdown of the...
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a new pharmacological class of drugs for treating Type 2 diabetes. They improve the capacity of the organism to control glycemia by increasing the levels of active incretins. Their mechanism of action is thus radically different from those of other ...
Merck have described 1,4-diazepine derivatives as potent dipeptidyl peptidase IV inhibitors for the treatment of diabetes with X studied extensively preclinically as a potential back-up compound to sitagliptan, marketed by Merck in 2006 as Januvia™ <2007BML49, 2007BML1903>. Sign in to downlo...
Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(1):38–47.Dipeptidyl peptidase‐4 inhibitors and pancreatitis risk: a meta‐analysis of randomized clinical trials[J] . M. Monami,I. Dicembrini,E. Mannucci....